PACIFIC SMILES GROUP LIMITED (PSQ)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

PSQ - PACIFIC SMILES GROUP LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 1.72
Index: ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$1.95

20 Nov
2024

0.000

OPEN

$1.95

0.000

HIGH

$1.95

21,696

LOW

$1.95

TARGET
$2.15 10.3% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
ACL . AHX . ALC . BMT . CAJ . DOC . EBO . HLS . M7T . MDR . MPL . MVF . NHF . RHC . SHL .
FNARENA'S MARKET CONSENSUS FORECASTS
PSQ: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx 5.0 7.3 xxx
DPS (cps) xxx 5.4 N/A xxx
EPS Growth xxx 100.0% 44.8% xxx
DPS Growth xxx 100.0% N/A xxx
PE Ratio xxx N/A 26.7 xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx 106.2% N/A xxx

Dividend yield today if purchased 3 years ago: 1.80%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 2.74

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 24/09 - ex-div 3.25c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx5.0
DPS All xxxxxxxxxxxxxxx5.4
Sales/Revenue xxxxxxxxxxxxxxx179.8 M
Book Value Per Share xxxxxxxxxxxxxxx37.9
Net Operating Cash Flow xxxxxxxxxxxxxxx32.8 M
Net Profit Margin xxxxxxxxxxxxxxx4.47 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx13.20 %
Return on Invested Capital xxxxxxxxxxxxxxx6.14 %
Return on Assets xxxxxxxxxxxxxxx4.47 %
Return on Equity xxxxxxxxxxxxxxx13.20 %
Return on Total Capital xxxxxxxxxxxxxxx9.35 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx22.0 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx15 M
Long Term Debt xxxxxxxxxxxxxxx61 M
Total Debt xxxxxxxxxxxxxxx75 M
Goodwill - Gross xxxxxxxxxxxxxxx13 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx18 M
Price To Book Value xxxxxxxxxxxxxxx5.01

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx3.8 M
Capex % of Sales xxxxxxxxxxxxxxx2.14 %
Cost of Goods Sold xxxxxxxxxxxxxxx134 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx32 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgan Stanley

30/08/2024

1

Overweight

$2.15

10.26%

Morgan Stanley believes investors will refocus on fundamentals for Pacific Smiles, which reported a better-than-expected FY24 result.

July was notable for the growth in 8.4% patient fees despite what is generally a seasonally weak period with pick-up generated from longer hours worked including weekends.

The broker believes the timing of the rollout, which was required to stop recently will impact on earnings. Management have conversely pointed to better appointment reminders and reduced cancellation rates.

The analyst raises earnings forecasts by around 14% for FY25 to FY26 with an accompanying lift in the target price to $2.15 from $1.90.

Overweight unchanged. Industry View: In-Line.

FORECAST
Morgan Stanley forecasts a full year FY25 EPS of 7.30 cents.
Morgan Stanley forecasts a full year FY26 EPS of 9.00 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Wilsons

04/09/2024

3

Market Weight

$1.80

-7.69%

Wilsons observes Pacific Smiles reported an 8.3% increase in gross patient fees in FY24 with trading softening towards the end of the fiscal year.

The broker notes an improvement in margins and the company ended the year with cash on hand of $17.7m with a 3.2c dividend.

Patient fees rose 10.4% in the weeks up to Aug 27 or 8.4% for an adjusted work-day.

Market weighting with a $1.80 target price, revised from $1.40.

FORECAST
Wilsons forecasts a full year FY25 dividend of 6.00 cents and EPS of 6.00 cents.
Wilsons forecasts a full year FY26 dividend of 7.70 cents and EPS of 7.70 cents.
Access Extra Coverage Research History >

PSQ STOCK CHART

FNArena News on PSQ

1
Next Week At A Glance – 23-27 Sep 2024

Sep 20 2024 - Weekly Reports
2
Australian Broker Call *Extra* Edition – Sep 04, 2024

Sep 04 2024 - Daily Market Reports
3
FNArena Corporate Results Monitor – 29-08-2024

Aug 29 2024 - Australia
4
Next Week At A Glance – 12-16 Aug 2024

Aug 09 2024 - Weekly Reports
5
Next Week At A Glance – 5-9 Aug 2024

Aug 02 2024 - Weekly Reports

Latest Healthcare services News

1
Building The No 3 Diagnostic Imaging Player

Jun 19 2024 - Small Caps
2
Capitol Health’s Higher Margin Outlook

Mar 13 2024 - Small Caps
3
Treasure Chest: Ramsay Health Care

Oct 26 2023 - Treasure Chest
4
Timing Seems Right For Alcidion Group

Jun 21 2023 - Small Caps
5
No Enthusiasm To Combine ACL & Healius

Mar 21 2023 - Australia
6
Dr Boreham’s Crucible: Alcidion

Dec 13 2022 - Small Caps
7
No Straight Covid-Relief For Ramsay Health Care

Nov 15 2022 - Australia
8
Dr Boreham’s Crucible: Mach7 Technologies

Nov 14 2022 - Small Caps
9
Negative Industry Trends Impact Australian Clinical Labs

Aug 12 2022 - Small Caps
10
Healius Offers Digital Carrot, Base Remains Soft

May 25 2022 - Australia